Press release content from PR Newswire. The AP news staff was not involved in its creation.
Constant Companion Releases AI-Powered Voice System With Instant Wireless Access To Improve Life For Aging Adults
March 15, 2021 GMT
Companion 4.0 from Constant Companion
SARASOTA, Fla., March 15, 2021 /PRNewswire/ Constant Companion, a fast-growing technology company which integrates its patented, voice-operated, AI-powered platform into popular smart speakers, is introducing Companion 4.0. The company’s purpose-built solutions for older adults and their caregivers facilitate better communication and monitoring of this growing at-risk population, keeping people engaged, connected, and protected.
The highlight of this just-released technology is a Smart Router which offers users a plug and play solution for reliable, predictable connections no matter where they live. Simply plug it in, and within 60 seconds, it locates the cellular tower with the strongest connection from over 200 net
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Everi Appoints Kate Lowenhar-Fisher Executive Vice President, Chief Legal Officer – General .
Everi Holdings Inc.March 15, 2021 GMT
LAS VEGAS, March 15, 2021 (GLOBE NEWSWIRE) Everi Holdings Inc. (NYSE: EVRI) (“Everi” or the “Company”), a premier provider of land-based and digital casino gaming products, financial technology and player loyalty solutions, today announced the appointment of Kate C. Lowenhar-Fisher as Executive Vice President, Chief Legal Officer – General Counsel, and Corporate Secretary, effective March 22, 2021, subject to customary regulatory approvals. Ms. Lowenhar-Fisher will have responsibility for the Company’s legal and regulatory compliance affairs and will report to Everi’s Chief Executive Officer, Michael Rumbolz.
Press release content from Business Wire. The AP news staff was not involved in its creation.
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
March 15, 2021 GMT
MALVERN, Pa. & SAN DIEGO (BUSINESS WIRE) Mar 15, 2021
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and provided an update on clinical trial activities.
ADVERTISEMENT
“Throughout 2020, PhaseBio made significant progress advancing our pipeline of therapies for serious cardiopulmonary diseases,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio Pharmaceuticals. “Our progress was driven by the continued global expansion of the pivotal Phase 3 REVERSE-IT trial of our lead product candidate bentracimab, which has now enrolled m